Back to results
US 2011/0217231 A1Published application
Anti-tenascin monoclonal antibody therapy for lymphoma
AssigneeDuke University
InventorsDavid Rizzieri, Darell D. Bigner, Michael Zalutsky
Life of this patent
Estimating the term…
Abstract
A method of treating lymphoma in a subject comprises administering to a subject afflicted with lymphoma an antibody that binds to tenascin in a therapeutically effective amount. Preferably the antibody is monoclonal antibody 81C6 or an antibody that binds to the epitope bound by monoclonal antibody 81C6. Preferably the antibody is labeled with or conjugated to a chemotherapeutic agent, particularly a radioisotope such as 131I.
Claims21
A method of treating lymphoma in a subject in need thereof, comprising:
- administering to a subject afflicted with lymphoma an antibody that binds to tenascin in a treatment effective amount.
A method of treating Non-Hodgkin's lymphoma in a human subject in need thereof, comprising:
- parenterally administering to a human subject afflicted with lymphoma a monoclonal antibody that binds to tenascin in a treatment effective amount;
- wherein said antibody is selected from the group consisting of monoclonal antibody 81C6 and antibodies that bind to the epitope bound by monoclonal antibody 81C6;
- and
- wherein said antibody is coupled to a radioisotope.
1 more element
Dependencies are inferred from the claim text.